PMID- 19339808
OWN - NLM
STAT- MEDLINE
DCOM- 20090904
LR  - 20220408
IS  - 1423-0097 (Electronic)
IS  - 1018-2438 (Linking)
VI  - 150
IP  - 1
DP  - 2009
TI  - Safety of two cluster schedules for subcutaneous immunotherapy in allergic 
      rhinitis or asthma patients sensitized to inhalant allergens.
PG  - 102-8
LID - 10.1159/000210436 [doi]
AB  - BACKGROUND: Subcutaneous immunotherapy (SCIT) usually requires a long titration 
      phase, which can be associated with various adverse events (AEs). OBJECTIVES: It 
      was the aim of this study to determine the safety of 2 cluster regimens for SCIT 
      in patients with allergic rhinitis, with or without mild or moderate allergic 
      asthma, who were sensitized to grass and/or tree pollen, or house dust mites 
      (HDM). PATIENTS AND METHODS: Adult patients were included in a European, 
      open-label, prospective trial. Pollen-allergic patients received grass pollen, 
      grass and olive pollen, or hazel, alder and birch pollen according to a 3-week 
      titration cluster. HDM-allergic patients received HDM extract according to a 
      2-week titration cluster. The safety of the titration phase was assessed in terms 
      of local and systemic AEs. RESULTS: The safety analysis included 157 patients: 
      110 received pollen and 47 HDM extract. During the cluster titration, 248 AE 
      episodes were reported in the pollen group and 113 in the HDM group; these were 
      mainly local reactions. Around one third of patients (30.9% pollen and 38.3% HDM) 
      did not experience any AE. In most cases (67.1% of pollen and 71.1% of HDM 
      patients), AEs did not lead to a change in titration schedule. No anaphylactic 
      reaction or other serious life-threatening systemic AEs were reported. Only 2 
      patients in the HDM group discontinued treatment because of AEs. CONCLUSIONS: 
      Rapid cluster titration was well tolerated in adults with allergic rhinitis, with 
      or without mild to moderate allergic asthma, due to pollen or HDM. This 
      short-titration, high-dose cluster regime may allow better patient compliance and 
      cost savings.
CI  - Copyright 2009 S. Karger AG, Basel.
FAU - Pfaar, O
AU  - Pfaar O
AD  - Center for Rhinology and Allergology Wiesbaden, Department of 
      Otorhinolaryngology, Head and Neck Surgery, University Hospital Mannheim, An den 
      Quellen 10, Wiesbaden DE-65189, Germany. oliver.pfaar@hno-wiesbaden.de
FAU - Klimek, L
AU  - Klimek L
FAU - Fischer, I
AU  - Fischer I
FAU - Sieber, J
AU  - Sieber J
FAU - Amoroso, S
AU  - Amoroso S
FAU - Moreno Aguilar, C
AU  - Moreno Aguilar C
FAU - Shah, K
AU  - Shah K
FAU - Mosges, R
AU  - Mosges R
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090402
PL  - Switzerland
TA  - Int Arch Allergy Immunol
JT  - International archives of allergy and immunology
JID - 9211652
RN  - 0 (Allergens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allergens/*administration & dosage/immunology
MH  - Animals
MH  - Asthma/*prevention & control
MH  - Desensitization, Immunologic/adverse effects/*methods
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pollen/immunology
MH  - Pyroglyphidae/immunology
MH  - Rhinitis, Allergic, Seasonal/*prevention & control
MH  - Young Adult
EDAT- 2009/04/03 09:00
MHDA- 2009/09/05 06:00
CRDT- 2009/04/03 09:00
PHST- 2008/07/18 00:00 [received]
PHST- 2008/12/16 00:00 [accepted]
PHST- 2009/04/03 09:00 [entrez]
PHST- 2009/04/03 09:00 [pubmed]
PHST- 2009/09/05 06:00 [medline]
AID - 000210436 [pii]
AID - 10.1159/000210436 [doi]
PST - ppublish
SO  - Int Arch Allergy Immunol. 2009;150(1):102-8. doi: 10.1159/000210436. Epub 2009 
      Apr 2.